Pancreatic serous cystadenoma

Summary

Pancreatic serous cystadenoma (MONDO:0002808) is a disease and 10 clinical trials. Top therapeutic interventions include fenofibrate. A subtype of pancreatic cystadenoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic serous cystadenoma
Mondo ID	MONDO:0002808
DOID	DOID:3917
ICD-11	1362470566
NCIT	C5712
UMLS	C1335316
MedGen	233833
Anatomy (UBERON)	UBERON:0001264
Is cancer (heuristic)	no

Also known as: pancreas serous cystadenoma · pancreatic microcystic adenoma · pancreatic serous cystadenoma · PSC · serous cystadenoma of pancreas · serous cystadenoma of the pancreas

Disease family

This is a subtype of pancreatic cystadenoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › adenoma › cystadenoma › pancreatic cystadenoma › pancreatic serous cystadenoma

Related subtypes (1): pancreatic mucinous cystadenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06905054	PHASE2	RECRUITING	Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
NCT06562361	EARLY_PHASE1	RECRUITING	A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups.
NCT03146936	Not specified	RECRUITING	Swiss Primary Sclerosing Cholangitis Cohort Study
NCT04753996	Not specified	RECRUITING	Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
NCT06252610	Not specified	NOT_YET_RECRUITING	PET/MRI of Primary Sclerosing Cholangitis
NCT06297993	Not specified	RECRUITING	Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
NCT06865924	Not specified	RECRUITING	Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
NCT03884179	Not specified	UNKNOWN	Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy
NCT04015310	Not specified	WITHDRAWN	Quantitative Magnetic Resonance Imaging in Biliary Disease: Health Economics Study
NCT05359497	Not specified	UNKNOWN	Value of MRCP+ And Liver Multiscan in the Management of Dominant Strictures in Primary Sclerosing Cholangitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FENOFIBRATE	4	1